✦ LIBER ✦

Use of differentiation inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia

✍ Scribed by Dr. Stephen J. Hoffman; William A. Robinson

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 366 KB
Volume: 28
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830280214

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Human acute myeloblastic leukemia cells

Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias

✍ Aude Charbonnier; Béatrice Gaugler; Danielle Sainty; Marina Lafage-Pochitaloff; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 2 views

Flow cytometric chemosensitivity analysi

Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: The use of 7AAD with antibodies to CD45 or CD34

✍ M. Pallis; J. Syan; N.H. Russell 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB 👁 1 views

Background: Flow cytometry is potentially suited to the chemosensitivity analysis of peripheral blood or bone marrow subpopulations in patients with leukaemia and myelodysplastic syndromes. Methods: The use of the fluorescent dye 7-aminoactinomycin (7AAD) on unfixed cells to measure loss of viabilit

Amplification of the MLL gene on double

Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome

✍ Berthold Streubel; Peter Valent; Ulrich Jäger; Martin Edelhäuser; Hannes Wandt; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

Gene amplification is one of the mechanisms for activating proto-oncogenes resulting in an enhanced expression of the corresponding gene product. By fluorescence in situ hybridization (FISH), amplification of the proto-oncogene MLL has been described only in seven patients with acute myeloid leukemi

Tumor lysis syndrome occurring after the

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

✍ Yang, Honghao; Rosove, Michael H.; Figlin, Robert A. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB 👁 2 views

Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of lowgrade or follicular non-Hodgkin's lymphoma (NHL). Because of its relatively benign side effect profile, it has been considered a nontoxic alternative to chemotherapy. Recently, however, tumor lysis syndrome (TLS) re